SurvivorNet, a privately owned US-based digital media company founded in 2017, offers streaming services focused on cancer information. Employing approximately 20 people, the company generated less than $25 million in revenue in 2023.
SurvivorNet reported on several cancer treatment developments. Doctors discussed personalized prostate cancer treatment plans, noting that treatment options depend on the cancer stage. A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), received approval for non-small cell lung cancer (NSCLC) patients with a common EGFR mutation, particularly benefiting those whose cancer progressed after prior treatment or who could not tolerate previous therapies. Information was also provided on radioligand therapy, such as Pluvicto, which delivers targeted radiation to prostate cancer cells. Finally, Dr. Tamara Lazic Strugar offered advice on navigating a cancer diagnosis, emphasizing the importance of continued movement and support systems.
Similar Companies
Subscribe for full access to SurvivorNet's profile
SurvivorNet offers products in the media and telecoms services industry. SurvivorNet's product portfolio comprises of media and TV services.
Subscribe for full access to SurvivorNet's products in full detail
SurvivorNet's revenues were less than $25M in 2023. All the revenue comes from video streaming.
Subscribe for full access to SurvivorNet's revenue in full detail
Subscribe for full access to SurvivorNet's products in full detail 
